Combination interferon-α2a and 13-cis-retinoic acid enhances radiosensitization of human malignant glioma cells in vitro

Clinical Cancer Research

Volumn 5, Issue 2, 1999, Pages 417-423

  Malone, Colin ^a   Schiltz, Patric M ^a   Nayak, Shankar K ^a   Shea, Michael W ^a   Dillman, Robert O ^a,b  

^a Cell Biol Lab Patty George Hoag C   (United States)

^b HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ISOTRETINOIN; ALPHA INTERFERON; ALPHA2 INTERFERON; ANTINEOPLASTIC AGENT; INTERFERON-ALPHA 2; RADIOSENSITIZING AGENT;

ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; GLIOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOSENSITIZATION; TUMOR REGRESSION; CELL CULTURE; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION EXPOSURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; COMBINED MODALITY THERAPY; GLIOMA; HUMANS; INTERFERON-ALPHA; ISOTRETINOIN; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0032588965     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kelley, K. A., Kirkwood, J. M., and Kapp, D. S. Glioblastoma multiforme: pathology, natural history, and treatment. Cancer Treat. Rep., 11: 1-26, 1984.
2. Black, P. M. Brain tumors. N. Engl. J. Med., 324: 1471-1476, 1555-1564, 1991.
3. Mahaley, M. S., Jr., Mettlin, C., Natarajan, N., Laws, E. R., Jr., and Peace, B.B. National survey of patterns of care for brain-tumor patients. J. Neurosurg., 71: 826-836, 1989.
4. Leibel, S. A., Scott, C. B., and Loeffler, J. S. Contemporary approaches to the treatment of malignant gliomas with radiation therapy. Semin. Oncol., 21: 198-219, 1994.
5. Chamberlain, M. C., Barba, D., Kormanik, P., and Shea, W. M. C. Stereotactic radiosurgery for recurrent gliomas. Cancer (Phila.), 74: 1342-1347, 1994.
6. Morantz, R. A., and Wara, W. M. Gamma knife radiosurgery in the treatment of brain tumors. Cancer Control, 2: 300-308, 1995.
7. Lesser, G. J., and Grossman, S. The chemotherapy of high-grade astrocytomas. Semin. Oncol., 21: 220-235, 1994.
8. Laws, E. R., Jr., and Thapar, K. Brain tumors. CA Cancer J. Clin., 43: 263-271, 1993.
9. Fine, H. A., Dar, K. B. G., Loeffler, J. S., Black, P. M., and Canellos, G. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer (Phila.), 71: 2582-2597, 1993.
10. Kalvakolanu, D. V., and Borden, E. C. An overview of the interferon system: signal transduction and mechanisms of action. Cancer Invest., 14: 25-53, 1996.
11. Drischillo, A., Mossman, K., Gray, M., and Sreevalsan, T. Potentiation of radiation injury by interferon. Am. J. Clin. Oncol., 5: 79-82, 1982.
12. 2-M phase of the cell cycle. Cancer Res., 47: 4338-4341, 1987.
13. Dillman, R. O., Wiemann, M., Oldham, R. K., Soori, G., Bury, M., Hafer, R., Church, C., and DePriest, C. Interferon α-2a and external beam radiotherapy in the initial management of patients with glioma: a trial of the National Biotherapy Study Group. Cancer Biother., 10: 265-271, 1995.
14. Rajkumar, S. V., Buckner, J. C., Schomberg, P. J., Cascino, T. L., Burch, P. A., and Dinapoli, R. P. Phase I evaluation of radiation combined with recombinant Interferon α-2a and BCNU for patients with high-grade glioma. Int. J. Radiat. Oncol. Biol. Phys., 40: 297-302, 1998.
15. Smith, M. A., Parkinson, D. R., Cheson, B. D., and Friedman, M. A. Retinoids in cancer therapy. J. Clin. Oncol., 70: 839-864, 1992.
16. Yung, W. K. A., Kyritsis, A. P., Gleason, M. J., and Levin, V. A. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin. Cancer Res., 2: 1931-1935, 1996.
17. Rutz, H. P., and Little, J. B. Modification of radiosensitivity and recovery from X-ray damage in vitro by retinoic acid. Int. J. Radiat. Oncol. Biol. Phys., 16: 1285-1288, 1989.
18. Lippman, S. M., Kavanaugh, J. J., Prededs-Espinoza, M., Delgaldillo-Madrueno, F., Paredes-Casillas, P., Hong, W. K., Massimini, G., Holdener, E. E., and Krakoff, I. H. 13-cis-Retinoic acid plus interferon-α2a for locally advanced squamous cell carcinoma of the cervix. J. Natl. Cancer Inst., 85: 499-500, 1993.
19. Lippman, S. M., Parkinson, D. R., Itri, L. M., Weber, R. S., Schantz, S. P., Ota, D. M., Schusterman, M. A., Kralcoff, I. H., Gutterman, J. U., and Hong, W. K. 13-cis-Retinoic acid and Interferon α-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J. Natl. Cancer Inst., 84: 235-241, 1992.
20. Hoffman, W., Kley, J., Schiller, U., Schlak, I., Blamberg, M., and Rodemann, H. P. Retinoids and interferon-α2a enhance the antiproliferative effect of radiation in cultured human squamous cell carcinoma lines. Proc. Am. Soc. Clin. Oncol., 14: 513, 1995.
21. DeLaney, T. F., Afridi, N., Taghian, A. G., Sanders, D. A., Fuleihan, N. S., Faller, D. V., and Nogueira, C. P. 13-cis-Retinoic acid with interferon-α2a enhances radiation cytotoxicity in head and neck squamous cell carcinoma in vitro. Cancer Res., 56: 2277-2280, 1996.
22. Ryu, S., Kim, O. B., Kim, S. H., He, S. Q., and Kim, J. H. In vitro radiosensitization of human cervical carcinoma cells by combined use of 13-m-retinoic acid and interferon-α2a. Int. J. Radiat. Oncol. Biol. Phys., 41: 869-873, 1998.
23. Lippman, S. M., Kavanaugh, J. J., Paredes, Delgaldillo, F., Hong, W. K., Figuerda, F., Olguin, A., Freedman, R., S., Massimini, G., Holdener, E. E., and Krakoff, I. H. 13-cis-Retinoic acid plus interferon-α2a and radiotherapy for locally advanced cancer of the cervix. Proc. Am. Soc. Clin. Oncol., 12: 257, 1993.
24. Park, T. K., Lee, J. P., Kim, S. N., Choi, S. M., Kudelka, A. P., and Kavanaugh, J. J. Interferon-α2a, 13-cis-retinoic acid and radiotherapy for locally advanced carcinoma of the cervix: a pilot study. Eur. J. Gynaecol. Oncol., 19: 35-38, 1998.
25. Schiltz, P. M., Malone, C., Dillman, R. O., Shea, W. M., and Nayak, S. K. Interferon α-2a combined with 13-cis-retinoic acid treatment produces enhanced radiosensitization of human glioma lines in vitro. Proc. Am. Assoc. Cancer Res., 38: A304, 1997.
26. Shea, W. M., Dillman, R. O., Mahadavi, K., Fong. W., Vander-Molen, L. V., Barth, N., and Sheehy, P. F. Radiotherapy with concurrent interferon α-2a and 13-cis-retinoic acid for treatment of high-grade malignant gliomas: a phase II trial of the National Biotherapy Study Group. Proc. Am. Soc. Clin. Oncol., 16: 408a, 1997.
27. Ramsay, J., Ward, R., and Bleehen, N. M. Radiosensitivity testing of human malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys., 24: 675-680, 1992.
28. Twentyman, P. R., Walls, G. A., and Wright, K. A. The response of tumor cells to radiation and cytotoxic drugs-a comparison of clonogenic and isotope uptake assays. Br. J. Cancer, 50: 625-631, 1984.
29. Elkind, M. M. The initial part of the survival curve: does it predict outcome of fractionated radiotherapy? Radiat. Res., 144: 425-436, 1988.
30. Mottram, J. C. Factors of importance in radiosensitivity of tumors. Br. J. Radiol., 9: 606-641, 1986.
31. Dillman, R. O., Nayak, S. K., and Beutel, L. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J. Immunother., 14: 65-69, 1993.
32. Dillman, R. O., Soori, G., Tai, D. F., Honeycutt, P., DePriest, C., and Church, C. Interferon α-2a and cis-retinoic acid for the treatment of squamous cell carcinoma: a preliminary report. J. Immunother., 20: 404, 1997.
33. Coleman, C. N., and Stevenson, M. A. Biologic basis for radiation therapy. Oncology, 10: 399-411, 1996.